Trials / Withdrawn
WithdrawnNCT05321940
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
A Pilot Safety Trial of STING-dependent Activators (STAVs) and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Juan C. Ramos, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to investigate whether the combination of STING-dependent Adjuvants (STAVs) and dendritic cell (DC) vaccine therapies will increase the body's ability to fight aggressive relapsed or refractory leukemias.
Conditions
- Refractory Leukemia
- Relapsed Leukemia
- Acute Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Adult T-Cell Leukemia/Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells | Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe. |
| BIOLOGICAL | Dendritic Cell Vaccine | 15-20 Million mature dendritic cells per dose administered via intravenous injection. |
Timeline
- Start date
- 2023-11-30
- Primary completion
- 2025-11-30
- Completion
- 2026-11-30
- First posted
- 2022-04-11
- Last updated
- 2023-12-04
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05321940. Inclusion in this directory is not an endorsement.